Preclinical and clinical studies: A preview of potential future applications of erythropoietic agents

Seminars in Hematology

Volumn 41, Issue SUPPL. 7, 2004, Pages 17-25

  Lewis, Lionel D ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; IFOSFAMIDE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BONE MARROW; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITION; DRUG MECHANISM; GASTROINTESTINAL TRACT; GENITAL SYSTEM; HEART; HEART MUSCLE ISCHEMIA; HEMATOPOIESIS; HUMAN; HYPOXIA; KIDNEY; LIVER; LUNG; NEUROPROTECTION; NONHUMAN; OXYGENATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETINA; RETINA DISEASE; REVIEW; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL; UTERINE CERVIX CANCER; VASCULAR ENDOTHELIUM;

EID: 10444280895     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.09.004     Document Type: Article

References (64)

1. B.J. Ania, V.J. Suman, V.F. Fairbanks Prevalence of anemia in medical practice Community versus referral patients Mayo Clin Proc 69 1994 730 735
2. L. Balducci Anemia, cancer, and aging Cancer Control 10 2003 478 486
3. S.P. Becerra, J. Amaral Erythropoietin--An endogenous retinal survival factor N Engl J Med 347 2002 1968 1970
4. R. Bianchi, B. Buyukakilli, M. Brines Erythropoietin both protects from and reverses experimental diabetic neuropathy Proc Natl Acad Sci U S A 101 2004 823 828
5. K.L. Blackwell, J.P. Kirkpatrick, S.A. Snyder Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin Cancer Res 63 2003 6162 6165
6. J.U. Blohmer, W. Wurschmidt, U. Petry Sixth interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study Sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer 2003 Presented at the American Society of Clinical Oncology, Chicago, IL, May 31-June 3
7. S. Bocker-Meffert, P. Rosenstiel, C. Rohl Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats Invest Opthalmol Vis Sci 43 2002 2021 2026
8. C. Bokemeyer, K. Oechsle, J.T. Hartmann Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer Br J Cancer 87 2002 1066 1071
9. C.F. Bolton, G.B. Young Uremic neuropathy, in Neurological Complications of Renal Disease 1990 Butterworth Boston, MA 76 107
10. C.B. Brezden, K.A. Phillips, M. Abdolell Cognitive function in breast cancer patients receiving adjuvant chemotherapy J Clin Oncol 18 2000 2695 2701
11. M.L. Brines, P. Ghezzi, S. Keenan Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury Proc Natl Sci Acad Sci U S A 97 2000 10526 10531
12. D.M. Brizel, R.K. Dodge, R.W. Clough Oxygenation of head and neck cancer Changes during radiotherapy and impact on treatment outcome Radiother Oncol 53 1999 113 117
13. Z. Cai, D.J. Manalo, G. Wei Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury Circulation 108 2003 79 85
14. Z. Cai, G.L. Semenza Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury Circulation 109 2004 2050 2053
15. J.J. Caro, M. Salas, A. Ward Anemia as an independent prognostic factor for survival in patients with cancer A systematic, quantitative review Cancer 91 2001 2214 2221
16. M. Celik, N. Cokmen, S. Erbayraktar Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury Proc Natl Sci Acad Sci U S A 99 2002 2258 2263
17. N.S. Chandel, E. Maltepe, E. Goldwasser Mitochondrial reactive oxygen species trigger hypoxia-induced transcription Proc Natl Acad Sci U S A 95 1998 1175 11720
18. P.H.M. Chaves, S.H. Mody, M.M. Najib Anemia in the elderly is associated with increased healthcare costs and resource utilization Blood 102 2003 2769 (abstr)
19. P.H.M. Chaves, R.C. Woodman, L.P. Fried Relationship between anemia and frailty status in older adults The Womens' Health and Aging Studies I and II Blood 102 2003 2773 (abstr)
20. Z.Z. Chong, J.Q. Kang, K. Maiese Erythropoietin Cytoprotection in vascular neuronal cells Curr Drug Targets Cardiovasc Hematol Disord 3 2003 141 154
21. H. Ehrenreich, M. Hasselblatt, C. Dembowski Erythropoietin therapy for acute stroke is both safe and beneficial Mol Med 8 2002 495 505
22. A.W. Fyles, M. Milosevic, R. Wong Oxygenation predicts radiation response and survival in patients with cervix cancer Radiother Oncol 48 1998 149 156
23. C.M. Glaser, W. Millesi, G.V. Kornek Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx Int J Radiat Oncol Biol Phys 50 2001 705 715
24. M.S. Gordon Managing anemia in the cancer patient old problems, future solutions Oncologist 7 2002 331 341
25. S.E. Graeber, S.B. Krantz Erythropoietin biology and clinical use Hematol Oncol Clin North Am 3 1989 369 400
26. C. Grimm, A. Wenzel, M. Groszer HIF-1 induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration Nat Med 8 2002 718 724
27. J.M. Guralnik, R.S. Eisenstaedt, L. Ferrucci The prevalence of anemia in persons age 65 and older in the United States Evidence for a high rate of unexplained anemia Blood 102 2003 3370 (abstr)
28. A.L. Harris Hypoxia--A key regulatory factor in tumour growth Nat Rev Cancer 2 2002 38 47
29. L.B. Harrison, M. Chadha, R.J. Hill Impact of tumor hypoxia and anemia on radiation therapy outcomes Oncologist 7 2002 492 508
30. K. Hassan, W. Simri, I. Rubenchik Effect of erythropoietin therapy on polyneuropathy in predialytic patients J Nephrol 16 2003 121 125
31. M. Henke, R. Laszig, C. Rube Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy Randomized, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260
32. E. Joosten, W. Pelemans, M. Hiele Prevalence and causes of anaemia in a geriatric hospitalized population Gerontology 38 1992 111 117
33. A.S. Junk, A. Mammis, S.I. Sawitz Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury Proc Natl Acad Sci U S A 99 2002 10659 10664
34. D.K. Kelleher, U. Mattheinsen, O. Thews Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats Cancer Res 56 1996 4728 4734
35. 2 measurements as predictive assay in the treatment of carcinoma of the uterine cervix Radiother Oncol 53 1999 99 104
36. BEST Investigators B. Leyland-Jones Breast cancer trial with erythropoietin alfa terminated unexpectedly Lancet Oncol 4 2003 459 460
37. T.J. Littlewood, E. Bajetta, J.W. Nortier Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy Results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2001 2865 2874
38. H.H. Marti, R.H. Wenger, L.A. Rivas Erythropoietin gene expression in human, monkey and murine brain Eur J Neurosci 8 1996 666 676
39. C. Moon, M. Krawczyk, D. Ahn Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats Proc Natl Acad Sci U S A 100 2003 11612 11617
40. National Comprehensive Cancer Network Practice Guidelines in Oncology, v Cancer and treatment-related anemia 2004 Available at: http://www.nccn.org/ physician_gls/f_guidelines.html
41. N.V. Olsen Central nervous system frontiers for the use of erythropoietin Clin Infect Dis 37 suppl 2003 S323 330
42. J.A. O'Shaugnessy, S. Vukelja, M. Savin Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy analysis of 6-month follow-up data 2002 Presented at the 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-14
43. J.A. O'Shaughnessy Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy Clin Breast Cancer 3 suppl 2002 S116 120
44. J.A. O'Shaughnessy Chemotherapy-induced cognitive dysfunction A clearer picture Clin Breast Cancer 4 suppl 2003 S89 94
45. J. O'Shaughnessy Chemotherapy-related cognitive dysfunction in breast cancer Semin Oncol Nurs 4 suppl 2003 17 24
46. N. Paffett-Lugassy, L.I. Zon Epo-EpoR signaling not required for cardiovascular or neural development Blood 100 2002 2277 (abstr)
47. C.J. Parsa, A. Matsumoto, J. Kim A novel protective effect of erythropoietin in the infarcted heart J Clin Invest 112 2003 999 1007
48. B.W. Penninx, J.M. Guralnik, G. Onder Anemia and decline in physical performance among older persons Am J Med 115 2003 104 110
49. I. Quirt, C. Robeson, C.Y. Lau Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy J Clin Oncol 19 2001 4126 4134
50. E.K. Rofstad, K. Sunfor, H. Lyng Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis Br J Cancer 83 2000 354 359
51. 2 histography in patients with advanced head and neck cancer Radiother Oncol 51 2000 31 37
52. M. Sakanaka, T.-C. Wen, S. Matsuda In vivo evidence that erythropoietin protects neurons from ischemic damage Proc Natl Sci Acad Sci U S A 95 1998 4635 4640
53. D. Shasha, M.J. George, L.B. Harrison Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy Cancer 98 2003 1072 1079
54. A.L. Siren, E. Nerlich, W. Poser Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain Acta Neuropathol (Berl) 101 2001 271 276
55. R.E. Smith, N.S. Tchekmedyian, D. Chan A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer Br J Cancer 88 2003 1851 1858
56. B.A. Teicher Physiologic mechanisms of therapeutic resistance Blood flow and hypoxia Hematol Oncol Clin North Am 9 1995 475 506
57. O. Thews, D.K. Kelleher, P. Vaupel Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors Cancer Res 61 2001 1358 1361
58. O. Thews, R. Koenig, D.K. Kelleher Enhanced radiosensitivity in experimental tumours erythropoietin treatment of chemotherapy-induced anaemia Br J Cancer 78 1998 752 756
59. E.M. Tong, E.R. Nissenson Erythropoietin and anemia Semin Nephrol 21 2001 190 203
60. S. Vadhan-Raj, B. Mirtsching, V. Charu Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks J Support Oncol 1 2003 131 138
61. F.S. van Dam, S.B. Schagen, M.J. Muller Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer High-dose versus standard-dose chemotherapy J Natl Cancer Inst 3 1998 210 218
62. J. Vansteenkiste, R. Pirker, B. Massuti Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 2002 1211 1220
63. P. Vaupel, O. Thews, M. Hoeckel Treatment resistance of solid tumors Med Oncol 18 2001 243 259
64. M.J. Weiss New insights into erythropoietin and epoetin alfa Mechanisms of action, target tissues, and clinical applications Oncologist 8 suppl 3 2003 18 29